Jonathan C. Fox Sells 5,000 Shares of Eidos Therapeutics Inc (EIDX) Stock

Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $23.11, for a total value of $115,550.00. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of EIDX opened at $23.38 on Thursday. The company has a market cap of $919.12 million and a price-to-earnings ratio of -12.57. Eidos Therapeutics Inc has a 52 week low of $8.89 and a 52 week high of $25.55.

Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). On average, sell-side analysts predict that Eidos Therapeutics Inc will post -1.3 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in EIDX. New York State Common Retirement Fund purchased a new position in shares of Eidos Therapeutics in the 4th quarter worth approximately $69,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Eidos Therapeutics in the 4th quarter worth approximately $104,000. Bank of New York Mellon Corp purchased a new position in shares of Eidos Therapeutics in the 3rd quarter worth approximately $137,000. JPMorgan Chase & Co. purchased a new position in shares of Eidos Therapeutics in the 3rd quarter worth approximately $167,000. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Eidos Therapeutics in the 4th quarter worth approximately $271,000. Hedge funds and other institutional investors own 30.15% of the company’s stock.

EIDX has been the subject of a number of recent research reports. BTIG Research initiated coverage on Eidos Therapeutics in a report on Wednesday. They set a “buy” rating for the company. Zacks Investment Research raised Eidos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. lowered Eidos Therapeutics from an “overweight” rating to a “neutral” rating and set a $29.00 price objective for the company. in a report on Wednesday, January 23rd. Finally, BMO Capital Markets initiated coverage on Eidos Therapeutics in a report on Friday, February 22nd. They set an “outperform” rating and a $28.00 price objective for the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Eidos Therapeutics has an average rating of “Buy” and a consensus target price of $27.00.

WARNING: “Jonathan C. Fox Sells 5,000 Shares of Eidos Therapeutics Inc (EIDX) Stock” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2019/04/18/jonathan-c-fox-sells-5000-shares-of-eidos-therapeutics-inc-eidx-stock.html.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Story: What is the Quick Ratio?

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.